DVT

NTHU Researchers Develop Ultrasonic Vortex Thrombolytic Device

Retrieved on: 
Friday, September 24, 2021
Health, Cardiology, Other Health, Medical Devices, Heart failure, Mortality, Mouse, Embolism, Epilepsy, Environmental science, Exhibition, National academy, Parkinson's disease, PE, Student, Pulmonary embolism, Deep vein thrombosis, Multimedia, Thrombectomy, Biomedical engineering, Stanford University, COVID-19, National, DVT, Microbubble, Thrombosis, Research, PNAS, Brain, Agitation, Bleeding, Industry, Vaccination, Lists of diseases, Department, Pharmaceutical industry, Medical imaging

Working with industrial partners, Yehs team has developed a 0.2-mm ultrasonic device, which can generate tornado-like ultrasonic vortex and create a strong turbulent around the thrombus, therefore increasing penetration of thrombolytic drugs and resulting in very effective thrombolysis.

Key Points: 
  • Working with industrial partners, Yehs team has developed a 0.2-mm ultrasonic device, which can generate tornado-like ultrasonic vortex and create a strong turbulent around the thrombus, therefore increasing penetration of thrombolytic drugs and resulting in very effective thrombolysis.
  • Yeh said that animal studies have shown results of 60% thrombus shrinkage in the mice brain after applying ultrasonic vortex for ten minutes, demonstrating the potential of fast treatment.
  • Yeh added that his team is also working on using ultrasonic vortex for noninvasive thrombolysis, which provides potential to treat embolisms in the brain.
  • Reflecting on how he first got interested in ultrasonic vortex, Yeh recalled that it was a family trip to a marine science museum ten years ago.

Global Anticoagulants Market (2021 to 2025) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 22, 2021
Health, Pharmaceutical, Blood, VTE, Anticoagulant, Tablet, Thrombosis, Infarction, Vein, Embolism, Stroke, Rivaroxaban, DIC, Deep vein thrombosis, Cancer, Patient, Dabigatran, Heart, Apixaban, Purpura, Cardiovascular disease, Prevalence, Growth, Artery, COVID-19, Capsule, DVT, Heparin, Warfarin, Birth control, Pharmaceutical industry

These drugs are used to treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT) - all potentially life-threatening conditions.

Key Points: 
  • These drugs are used to treat strokes, myocardial infarctions, pulmonary embolisms, disseminated intravascular coagulation (DIC) and deep vein thrombosis (DVT) - all potentially life-threatening conditions.
  • The global anticoagulants market has increased progressively over the years and the market growth was bolstered in 2020 owing to spread of COVID-19 pandemic.
  • The global anticoagulants market is supported by various growth drivers such as growing geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease, etc.
  • However, the growth of the market would be supported by numerous market trends such as rising prevalence of venous thromboembolism (VTE), direct oral anticoagulants (DOACs), etc.

ASCP Recognizes 2021 Choosing Wisely Champions for Reducing Unnecessary Testing and Waste in Health Care

Retrieved on: 
Wednesday, September 22, 2021
ABIM, Thrombosis, DLM, Henry Ford Hospital, Choosing Wisely, Policy, Henry Ford Health System, Quest Diagnostics, Society, Emergency department, Pacific Northwest, Pulmonary embolism, Patient, American Society for Clinical Pathology, ASCP, Physician, Certification, Hospital, American Board of Commissioners for Foreign Missions, Consumer, Method, Twitter, Gaps, ARUP, Internal medicine, MPH, PeaceHealth, LSC, Professional, Facebook, DVT, American Board of Internal Medicine, Veterans' affairs, Laboratory, Marie Cassidy, Education, Veteran, Tutoring, Medical device, Medicine

CHICAGO, Sept. 21, 2021 /PRNewswire-PRWeb/ -- The American Society for Clinical Pathology (ASCP) has named several healthcare leaders and health systems as its ASCP 2021 Choosing Wisely Champions for their successful efforts to drive effective test utilization and reduce waste in health care.

Key Points: 
  • CHICAGO, Sept. 21, 2021 /PRNewswire-PRWeb/ -- The American Society for Clinical Pathology (ASCP) has named several healthcare leaders and health systems as its ASCP 2021 Choosing Wisely Champions for their successful efforts to drive effective test utilization and reduce waste in health care.
  • ASCP will virtually present its 2021 Choosing Wisely Champions on October 20 from 2-3 p.m. Eastern time, during the ASCP 2021 Annual Meeting's 'Path to Boston' Choosing Wisely session.
  • ARUP Consultative Services collaborates with health systems nationwide to implement Choosing Wisely guidelines that optimize both reference and in-house laboratory test utilization.
  • Since 2013, Dr. Sharma has championed and helped implement the Choosing Wisely goals across the Henry Ford Health System.

Avion Pharmaceuticals recognizes Menopause Awareness Month by announcing the addition of Divigel® (estradiol gel) 0.1% to their product portfolio

Retrieved on: 
Monday, September 20, 2021
Dementia, Flash, Myocardial infarction, Megasphaera, National Center for Biotechnology Information, Therapy, Health, Stroke, WHI, FDA, Pulmonary embolism, Multimedia, Patient, Institute, MI, Progestogen, CEO, NPA, LLC, Woman, National Center for Health Research, DC, CE, Menopause, Prenatal care, DVT, Breast cancer, Estimation, MPA, Reproductive health, Pharmaceutical industry, Birth control, Dietary supplement

ALPHARETTA, Ga., Sept. 20, 2021 /PRNewswire/ --Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, today announced the addition of Divigel (estradiol gel) 0.1%the #1 prescribed transdermal estrogen gel*to the company's growing women's health portfolio.

Key Points: 
  • ALPHARETTA, Ga., Sept. 20, 2021 /PRNewswire/ --Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, today announced the addition of Divigel (estradiol gel) 0.1%the #1 prescribed transdermal estrogen gel*to the company's growing women's health portfolio.
  • The product is supplied in a discreet gel pack and is applied once daily to a small area of the upper thigh.
  • As a part of their observance of Menopause Awareness Month, Avion will present a product theater on Friday, Sept. 24, during the North American Menopause Society Annual Meeting in Washington, DC.
  • Divigel (estradiol gel) 0.1% is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Dr. Paul Gagne Launches Vascular Care Connecticut to Deliver Patient-Centered Care to Darien

Retrieved on: 
Monday, September 20, 2021
Managed Care, General Health, Health, Surgery, Society for Vascular Surgery, Mouth ulcer, NYU, Compliance, Diagnosis, Patient, Health, Varicose veins, IVUS, FACS, Method, Environment, Vascular disease, New York University Grossman School of Medicine, RVT, Journal, Â, DVT, Peripheral artery disease, Safety, Venography, U.S. Navy Diving Manual, Private practice, Blood vessel, Society, Aortic aneurysm, Dentistry, Medical imaging

By augmenting the local hospital systems with specialized outpatient care, vascular centers such as ours can play a vital role in optimizing patient care locally, said Dr. Gagne.

Key Points: 
  • By augmenting the local hospital systems with specialized outpatient care, vascular centers such as ours can play a vital role in optimizing patient care locally, said Dr. Gagne.
  • Vascular Care Connecticut is dedicated to being on the cutting edge of innovation and new technologies for vascular disease and providing patients the care they need in a convenient and uncomplicated environment.
  • Vascular Care Connecticut is committed to the prevention, diagnosis, and treatment of vascular disease.
  • Vascular Care Connecticut brings together decades of experience to offer unparalleled care in Connecticut.

New Access Vascular Clinical Studies Find Catheters Composed of Advanced Biomaterials Significantly Reduce Complication Rates

Retrieved on: 
Monday, September 20, 2021
Patent, Water, Patient, FDA, Deep vein thrombosis, Catheter, Association, AVA, CEO, Access, Family, PICC, Technology, DVT, Thrombosis, Phlebitis, Infection, AVI, Data analysis, GLOBE, RN, Medical imaging

Presented at the Association for Vascular Access (AVA) Annual Scientific Meeting 2021, these early findings highlight the potential for catheters made from advanced biomaterials to reduce patient risks, clinician frustration, and medical expense in vascular access and other applications.

Key Points: 
  • Presented at the Association for Vascular Access (AVA) Annual Scientific Meeting 2021, these early findings highlight the potential for catheters made from advanced biomaterials to reduce patient risks, clinician frustration, and medical expense in vascular access and other applications.
  • The first retrospective clinical study compared complication rates such as occlusions and replacements in 61 standard PICCs and 60 HydroPICCs, respectively.
  • The second retrospective study compared complication rates of occlusions, replacements, deep vein thrombosis (DVT), and phlebitis in 100 standard midline catheters and 100 HydroMID catheters.
  • This clinical data proves its possible to transform patient outcomes and significantly reduce total medical expenses, said James Biggins, CEO of Access Vascular.

Global Inferior Vena Cava Market (2021 to 2026) - Featuring ALN, Argon Medical and Cook Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 7, 2021
Health, Medical Devices, Cardiology

An inferior vena cava filter (IVC) is a medical device that is implanted into the inferior vena cava for deep venous thrombosis (DVT) or pulmonary embolism (PE).

Key Points: 
  • An inferior vena cava filter (IVC) is a medical device that is implanted into the inferior vena cava for deep venous thrombosis (DVT) or pulmonary embolism (PE).
  • Geographically, North America and Europe dominate the IVC filter market while the Asia Pacific is a region of high growth.
  • So, when the significantly less invasive inferior vena cava (IVC) filter was invented, it was accepted and adopted rather quickly.
  • The Inferior Vena Cava Filter market is anticipated to grow at a high rate owing to this increasing prevalence.

Global Vena Cava Filters Market (2021 to 2026) - Featuring ALN International, Argon Medical Devices and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, August 27, 2021
Medical Devices, Health, Thrombosis, DVT, Laboratory, Catheter, Incidence, Inferior vena cava, First Nations in Ontario, Coronavirus, Inferior vena cava filter, World Health Organization, Person, Cava, Death, World, Heart, Awareness, Lists of countries and territories, COVID-19, Patient, Degenerative disease, Pulmonary embolism, Recurrence, Venae cavae, United Nations, Embolism, Pharmaceutical industry

The vena cava filters are either permanently placed or are retrievable, depending on their use to prevent the recurrence of pulmonary embolism.

Key Points: 
  • The vena cava filters are either permanently placed or are retrievable, depending on their use to prevent the recurrence of pulmonary embolism.
  • The increasing incidence of such diseases will support the market growth of the vena cava filters market as more patients will require it for their treatment.
  • The vena cava filters treatment is a costly treatment which makes it unaffordable for a majority of patients.
  • The Covid-19 pandemic moderately impacted the global vena cava filters market as due to the nationwide lockdown restrictions; many patients deferred their ongoing treatments to avoid public places which hampered the market growth.

Sky Harbour Capital LLC, a subsidiary of Sky Harbour LLC, a Developer of US Airport Infrastructure, Agrees to $166,340,000 Bond Sale Through Public Finance Authority

Retrieved on: 
Wednesday, August 25, 2021
Other Transport, Finance, Air, Transport, Professional Services, Other Travel, Transportation, Logistics, Supply Chain Management, Travel, Other Professional Services, Company, Telecommunication, Miami-Opa Locka Executive Airport, DVT, Airport, Privacy, Sugar Land Regional Airport, Nixon Peabody, Acquisition, Maintenance, Nashville International Airport, Home-based program, Efficiency, Nasdaq, Phoenix Deer Valley Airport, Advertising, LLP, BNY Mellon, Investment, 2009 Davis Cup, Bank, Safety, Morrison & Foerster, Environment, Westchester County Airport, Sale, Goldman Sachs, Aviation, Matteo Pellicone Ranking Series 2021, Barclays Capital Inc. v. Theflyonthewall.com, Inc., SHG, Centennial Airport, View, Bookrunner, Airline, Insurance, Sky Harbour LLC, Boston Omaha Corporation, SKY HARBOUR LLC, BOSTON OMAHA CORPORATION

As part of the plan of finance, SHG will be contributing $68 million in equity to the Obligated Group.

Key Points: 
  • As part of the plan of finance, SHG will be contributing $68 million in equity to the Obligated Group.
  • Sky Harbour LLC is an aviation infrastructure company building the first nationwide network of Home-Basing solutions for business aircraft.
  • Sky Harbour hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
  • Sky Harbour LLC is incorporated in Delaware and headquartered at Westchester County Airport, New York.

Precision Medical Products CEO Jeremy Perkins Named A Top 50 Healthcare Technology CEO of 2021

Retrieved on: 
Tuesday, August 24, 2021
PReVENT, Industry, DVT, Perkin, Medicine, Marketing, IEEE Medal for Innovations in Healthcare Technology, Deep vein thrombosis, Multimedia, Risk, Patient, Technology, Pharmaceutical industry, Medical imaging

ROCKLIN, Calif., Aug. 24, 2021 /PRNewswire/ -- Precision Medical CEO Jeremy Perkins has been named a Top 50 CEO in Healthcare Technology by The Healthcare Technology Report.

Key Points: 
  • ROCKLIN, Calif., Aug. 24, 2021 /PRNewswire/ -- Precision Medical CEO Jeremy Perkins has been named a Top 50 CEO in Healthcare Technology by The Healthcare Technology Report.
  • This recognition occurs as Precision Medical Products continues to expand its hospital-to-home offerings, including the Circul8 Pro, VenaOneTM, and PreVent products.
  • Prior to launching Precision Medical Products in 2010, Perkins earned a reputation for sales and marketing excellence.
  • About Precision Medical Products: Since launching as a self-funded startup in 2010, Precision Medical Products has been helping patients recover from surgery, using its innovative products, programs and DVT prevention offerings.